Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00008359
First received: January 6, 2001
Last updated: January 17, 2013
Last verified: January 2013
History of Changes
  Purpose

RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects.

PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy.


Condition Intervention Phase
Cancer
 Drug: caspofungin acetate
Drug: liposomal amphotericin B
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia

Resource links provided by NLM:

MedlinePlus related topics: Cancer Fever
Genetic and Rare Diseases Information Center resources: Lymphosarcoma Multiple Myeloma Kidney Cancer Renal Cancer Neuroblastoma Myeloid Leukemia Chronic Myeloid Leukemia Myelofibrosis Hodgkin Lymphoma Myelodysplastic Syndromes Waldenstrom Macroglobulinemia Ovarian Epithelial Cancer Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Acute Myeloid Leukemia Acute Non Lymphoblastic Leukemia Acute Lymphoblastic Leukemia Follicular Lymphoma Polycythemia Vera Essential Thrombocythemia Granulocytopenia Lymphoma, Large-cell B-cell Lymphoma Chronic Myelomonocytic Leukemia Burkitt Lymphoma Anaplastic Large Cell Lymphoma Diffuse Large B-Cell Lymphoma Testicular Cancer Mantle Cell Lymphoma Gestational Trophoblastic Tumor Mycosis Fungoides Hairy Cell Leukemia Cutaneous T-cell Lymphoma Lymphoblastic Lymphoma Wilms' Tumor Leukemia, T-cell, Chronic Large Granular Lymphocyte Leukemia Aggressive NK Cell Leukemia Primary Central Nervous System Lymphoma Sezary Syndrome AL Amyloidosis Ovarian Germ Cell Tumor Choriocarcinoma Plasmablastic Lymphoma Lymphoma, Large-cell, Immunoblastic Angioimmunoblastic T-cell Lymphoma Angioimmunoblastic Lymphadenopathy With Dysproteinemia Monoclonal Gammopathy of Undetermined Significance Adult T-cell Leukemia/lymphoma Anaplastic Plasmacytoma Testicular Seminoma Testicular Yolk Sac Tumor Embryonal Carcinoma Polyembryoma
U.S. FDA Resources

Further study details as provided by Memorial Sloan Kettering Cancer Center:
Study Start Date: August 2000
Primary Completion Date: March 2003 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Compare the number of successful treatment outcomes among patients treated with caspofungin acetate vs amphotericin B liposomal for persistent fever and neutropenia following cancer therapy, in terms of survival for 7 days after study drug, resolution of fever, treatment of any baseline fungal infection, absence of breakthrough fungal infection during and for 7 days after study drug, and absence of study drug discontinuation due to toxicity or lack of efficacy.
  • Compare the incidence of nephrotoxicity in patients treated with these regimens.
  • Compare the incidence of infusion-related adverse events within 1 hour of the infusion in patients treated with these regimens.
  • Compare the incidence of treatment discontinuation due to drug-related adverse events, frequency of drug-related events, number of breakthrough fungal infections, and number of successfully treated baseline fungal infections in patients treated with these regimens.
  • Compare incidence of required dose increase due to inadequate clinical response in patients treated with these regimens.
  • Compare the time to resolution of fever in patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to high-risk (prior allogeneic bone marrow transplantation or prior chemotherapy for relapse of acute leukemia) vs low-risk and prior prophylactic antifungal therapy during chemotherapy (yes vs no). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive caspofungin acetate IV over 1 hour followed by placebo IV over 2 hours.
  • Arm II: Patients receive placebo IV over 1 hour followed by amphotericin B liposomal IV over 2 hours.

Treatment repeats daily for up to 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed at 7 and 14 days after study drug discontinuation.

PROJECTED ACCRUAL: A total of 1060 patients (530 per arm) will be accrued for this study.

  Eligibility
Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Leukemia, lymphoma, or other cancer that has been previously treated with chemotherapy or bone marrow or peripheral blood stem cell transplantation
  • Absolute neutrophil count less than 500/mm^3 for past 96 hours and not expected to recover in next 48 hours
  • Received at least 96 hours of parenteral systemic antibacterial therapy
  • Fever greater than 38.0 degrees Celsius

  • Adequately managed bacterial infection allowed if all of the following are true:

    • Negative blood cultures
    • Received at least 5 days of antibiotics to which any bacterial isolates are sensitive
    • Surgical drainage of any abscess fluid or surgical debridement of infected tissues
    • Removal of infected catheters
  • No invasive fungal infection
  • Not previously enrolled on this study

PATIENT CHARACTERISTICS:

Age:

  • 16 and over

Performance status:

  • Karnofsky 30-100%

Life expectancy:

  • At least 5 days

Hematopoietic:

  • Platelet count at least 5,000/mm^3
  • INR no greater than 1.6 (no greater than 4.0 if receiving anticoagulants)

Hepatic:

  • Bilirubin no greater than 3 times upper limit of normal (ULN)
  • AST or ALT no greater than 5 times ULN
  • Alkaline phosphatase no greater than 3 times ULN
  • No acute hepatitis or cirrhosis

Renal:

  • Not specified

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • No allergy, hypersensitivity, or prior serious reaction to any echinocandin antifungal or amphotericin B formulation
  • No other condition or illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics

Chemotherapy:

  • See Disease Characteristics
  • No concurrent investigational antineoplastic therapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • At least 10 days since prior parenteral amphotericin B
  • At least 14 days since prior investigational antibiotic, antifungal, or immunosuppressive drug
  • No concurrent rifampin or cyclosporine
  • No other concurrent investigational antibiotic, antifungal, or immunosuppressive drug
  • No concurrent alcohol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00008359

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Kent Sepkowitz, MD Memorial Sloan Kettering Cancer Center
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00008359     History of Changes
Other Study ID Numbers: 00-085  MSKCC-00085  MERCK-026-01  NCI-G00-1898 
Study First Received: January 6, 2001
Last Updated: January 17, 2013
Health Authority: United States: Federal Government

Keywords provided by Memorial Sloan Kettering Cancer Center:
stage I adult Hodgkin lymphoma
stage II adult Hodgkin lymphoma
stage III adult Hodgkin lymphoma
stage IV adult Hodgkin lymphoma
stage IV breast cancer
stage IIIA breast cancer
monoclonal gammopathy of undetermined significance
stage IIIB breast cancer
recurrent adult Hodgkin lymphoma
stage I cutaneous T-cell non-Hodgkin lymphoma
stage II cutaneous T-cell non-Hodgkin lymphoma
stage III cutaneous T-cell non-Hodgkin lymphoma
stage IV cutaneous T-cell non-Hodgkin lymphoma
recurrent cutaneous T-cell non-Hodgkin lymphoma
isolated plasmacytoma of bone
 extramedullary plasmacytoma
refractory multiple myeloma
stage II ovarian epithelial cancer
stage III ovarian epithelial cancer
stage IV ovarian epithelial cancer
recurrent ovarian epithelial cancer
disseminated neuroblastoma
recurrent neuroblastoma
recurrent Wilms tumor and other childhood kidney tumors
stage 0 chronic lymphocytic leukemia
Waldenstrom macroglobulinemia
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
stage I chronic lymphocytic leukemia

Additional relevant MeSH terms:
Neutropenia
Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases
Amphotericin B
Liposomal amphotericin B
Caspofungin
 Echinocandins
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents

ClinicalTrials.gov processed this record on September 29, 2016